- Home
- MLTX vs MDXG Comparison
MLTX vs MDXG Comparison
Compare MLTX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLTX | MDXG |
|---|---|---|
| Founded | 2021 | 2006 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MLTX | MDXG |
|---|---|---|
| Price | $17.67 | $4.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $24.80 | $10.00 |
| AVG Volume (30 Days) | ★ 1.2M | 864.4K |
| Earning Date | 06-01-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $15.20 |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $5.95 | $4.79 |
| 52 Week High | $62.75 | $8.29 |
Technical Indicators
Market Signals| Indicator | MLTX | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 31.86 |
| Support Level | $14.84 | N/A |
| Resistance Level | $19.15 | $7.41 |
| Average True Range (ATR) | 0.99 | 0.20 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 54.74 | 22.60 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.